Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Leukemia 12Leukemia, Myeloid, Chronic-Phase 7Leukemia, Myeloid, Acute 7Blast Crisis 7Neoplasms 6Leukemia, Myeloid, Accelerated Phase 6Myeloproliferative Disorders 5Carcinoma, Non-Small-Cell Lung 5Neoplasms by Histologic Type 4Leukemia, Myeloid 4Hematologic Diseases 4Bone Marrow Diseases 4Myelodysplastic Syndromes 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Immunoproliferative Disorders 2Immune System Diseases 2Hematologic Neoplasms 2Gastrointestinal Stromal Tumors 2Gastrointestinal Neoplasms 2Breast Neoplasms 2Thyroid Neoplasms 1Thrombocytosis 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Primary Myelofibrosis 1Piebaldism 1

Interventions

Gemcitabine 15130-nm albumin-bound paclitaxel 10Albumin-Bound Paclitaxel 7Oxaliplatin 5Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4Cisplatin 3Cetuximab 3Bevacizumab 3pembrolizumab 2napabucasin 2Pemetrexed 2PEGPH20 2MK-4721 2Irinotecan 2tremelimumab 1selinexor 1relacorilant 1ponatinib 1neratinib 1irinotecan sucrosofate 1folfirinox 1ensituximab 1durvalumab 1contrast agent BR1 1cobimetinib 1ceritinib 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Pancreatic Ductal × ponatinib × Clear all
NCT06813079 2025-02-18

Using Tumor Models to Determine Treatments

University Health Network, Toronto

Phase 2 Not yet recruiting
25 enrolled
Gastrointestinal

Carcinoma, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡